| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2014-11-08 | daclatasvir with asunaprevir and beclabuvir | patients with genotype 1 hepatitis C virus |
BMS (USA - NY) | Infectious diseases | |
| 2014-11-07 | IGSC 20 percent (20 percent concentration subcutaneous immunoglobulin treatment) | primary immunodeficiencies |
2-3 | Baxter (USA - IL) | Immunological diseases - Rare diseases |
| 2014-11-07 | ACE910 (anti-factor IXa x anti-factor X humanized bispecific antibody) | hemophilia A |
1 | Chugai Pharmaceutical (Japan) Roche (Switzerland) | Hematological diseases - Genetic diseases Rare diseases |
| 2014-11-07 | Ery-asp®/Graspa® (eryaspase - L-asparaginase loaded erythrocytes) | acute lymphoblastic leukemia (ALL) | Erytech (France) | Cancer - Oncology | |
| 2014-11-07 | QNASL® (Beclomethasone Dipropionate) Nasal Aerosol | perennial allergic rhinitis (PAR) |
3 | Teva Pharmaceutical Industries (Israel) | Allergic diseases - Immunological diseases |
| 2014-11-06 | ofatumumab (Arzerra®) | patients with relapsed chronic lymphocytic leukemia (CLL) who responded to treatment at relapse |
3 | GSK (UK) Genmab (Denmark) | Cancer - Oncology |
| 2014-11-06 | ALX-0171 | Respiratory Syncytial Virus (RSV) infections |
preclinical | Ablynx (Belgium) | Respiratory diseases - Infectious diseases |
| 2014-11-06 | AMG 224 | multiple myeloma | 1 | Amgen (USA - CA) | Cancer - Oncology |
| 2014-11-06 | lorcaserin HCl | overweight or obese patients with and without type 2 diabetes mellitus |
3 | Eisai (Japan) Arena Pharmaceuticals (USA - CA) | Metabolic diseases |
| 2014-11-06 | duvelisib (IPI-145) | blood cancers, including indolent non-Hodgkin lymphoma (iNHL) and chronic lymphocytic leukemia (CLL) | 1 | Infinity Pharmaceuticals (USA - MA) | Cancer - Oncology |
| 2014-11-06 | GSK2586184 (formerly GLPG0778) | psoriasis |
2 | GSK (UK) | Autoimmune diseases- Dermatological diseases |
| 2014-11-06 | imetelstat | myelofibrosis, acute myeloid leukemia |
Geron (USA - CA) | Rare diseases | |
| 2014-11-06 | MM-398 (nanoliposomal irinotecan injection) | recurrent high grade glioma |
1 | Merrimack Pharmaceuticals (USA - MA) | Cancer - Oncology |
| 2014-11-05 | EverFlex™ and Protégé™ GPS™ self-expanding stent systems | lesions of the common and external iliac arteries |
Covidien (Ireland) | Cardiovascular diseases | |
| 2014-11-05 | BL-7010 | celiac disease |
1-2 | BioLineRx (Israel) | Autoimmune diseases - Inflammatory diseases |
| 2014-11-04 | gevokizumab | pyoderma gangrenosum |
3 | Xoma (USA - CA) | Rare diseases |
| 2014-11-04 | THR-18 | acute ischemic stroke |
2 | D-Pharm (Israel) | Cerebrovascular diseases |
| 2014-11-04 | Cevira® (hexaminolevulinate) | human papilloma virus (HPV) related disease of the cervix |
2b | Photocure (Norway) | Infectious diseases - Cancer - Oncology |
| 2014-11-04 | SilverHawk™ and TurboHawk ™ directional atherectomy systems | peripheral artery disease |
Covidien (Ireland) | Cardiovascular diseases | |
| 2014-11-04 | liraglutide 3 mg | induction and maintenance of weight loss in overweight or obese people with type 2 diabetes |
3a | Novo Nordisk (Denmark) | Metabolic diseases |
